5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 6.71▲ | 6.73▼ | 6.71▲ | 6.87▼ | 6.71▲ |
MA10 | 6.71▲ | 6.74▼ | 6.80▼ | 6.89▼ | 6.38▲ |
MA20 | 6.73▼ | 6.83▼ | 6.86▼ | 6.69▲ | 4.44▲ |
MA50 | 6.73▼ | 6.86▼ | 6.90▼ | 6.15▲ | 3.98▲ |
MA100 | 6.81▼ | 6.89▼ | 6.77▼ | 4.04▲ | 6.62▲ |
MA200 | 6.87▼ | 6.76▼ | 6.71▲ | 3.43▲ | 6.52▲ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.000▼ | -0.013▼ | -0.025▼ | -0.053▼ | 0.319▲ |
RSI | 48.556▼ | 41.929▼ | 42.465▼ | 53.077▲ | 70.953▲ |
STOCH | 41.026 | 35.011 | 15.621▼ | 54.972 | 83.653▲ |
WILL %R | -46.154 | -73.846 | -84.685▼ | -57.851 | -12.693▲ |
CCI | -21.525 | -65.247 | -87.251 | -7.550 | 67.964 |
MA | $TNGX Price Crossed Below MA(13) | Set Alert |
Tuesday, August 05, 2025 05:24 PM
Tango Therapeutics (NASDAQ:TNGX), a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025.
|
Tuesday, August 05, 2025 05:00 PM
Tango Therapeutics (NASDAQ:TNGX), a biotechnology firm advancing targeted oncology therapies, posted its second quarter results on August 5, 2025.
|
Monday, August 04, 2025 06:03 AM
Hyster Yale Inc (NYSE:HY) is set to release its Q2 2025 earnings on Aug 5, 2025. The consensus estimate for Q2 2025 revenue is $936.90 million, and the earnings are expected to come in at -$0.39 per ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
25/08/25 | 6.85 | 6.94 | 6.63 | 6.72 | 1,048,500 |
22/08/25 | 7.04 | 7.19 | 6.80 | 6.90 | 1,503,210 |
21/08/25 | 6.68 | 7.04 | 6.60 | 7.01 | 712,640 |
20/08/25 | 6.83 | 7.01 | 6.69 | 6.75 | 1,043,400 |
19/08/25 | 7.35 | 7.42 | 6.63 | 6.96 | 2,851,512 |
18/08/25 | 6.80 | 7.23 | 6.78 | 7.22 | 2,368,287 |
15/08/25 | 6.97 | 7.01 | 6.761 | 6.77 | 1,017,500 |
14/08/25 | 6.74 | 6.965 | 6.65 | 6.92 | 639,656 |
13/08/25 | 6.85 | 7.15 | 6.60 | 6.88 | 1,249,300 |
12/08/25 | 6.54 | 6.84 | 6.39 | 6.76 | 1,061,800 |
|
|
||||
|
|
||||
|
|